ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
76.54
+1.77 (2.37%)
Aug 14, 2026, 4:00 PM EDT - Market closed
ANI Pharmaceuticals Revenue
ANI Pharmaceuticals had revenue of $266.04M in the quarter ending June 30, 2026, with 25.87% growth. This brings the company's revenue in the last twelve months to $978.38M, up 30.90% year-over-year. In the year 2025, ANI Pharmaceuticals had annual revenue of $883.37M with 43.78% growth.
Revenue (ttm)
$978.38M
Revenue Growth
+30.90%
P/S Ratio
1.68
Revenue / Employee
$1,008,638
Employees
970
Market Cap
1.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 883.37M | 268.99M | 43.78% |
| Dec 31, 2024 | 614.38M | 127.56M | 26.20% |
| Dec 31, 2023 | 486.82M | 170.43M | 53.87% |
| Dec 31, 2022 | 316.39M | 100.25M | 46.38% |
| Dec 31, 2021 | 216.14M | 7.66M | 3.67% |
| Dec 31, 2020 | 208.48M | 1.93M | 0.93% |
| Dec 31, 2019 | 206.55M | 4.97M | 2.47% |
| Dec 31, 2018 | 201.58M | 24.73M | 13.99% |
| Dec 31, 2017 | 176.84M | 48.22M | 37.49% |
| Dec 31, 2016 | 128.62M | 52.30M | 68.53% |
| Dec 31, 2015 | 76.32M | 20.35M | 36.36% |
| Dec 31, 2014 | 55.97M | 25.89M | 86.06% |
| Dec 31, 2013 | 30.08M | 9.71M | 47.67% |
| Dec 31, 2012 | 20.37M | 19.94M | 4,581.27% |
| Dec 31, 2011 | 435.16K | -2.04M | -82.41% |
| Dec 31, 2010 | 2.47M | 1.22M | 96.67% |
| Dec 31, 2009 | 1.26M | -2.52M | -66.73% |
| Dec 31, 2008 | 3.78M | 3.29M | 666.82% |
| Dec 31, 2007 | 493.05K | -13.95M | -96.59% |
| Dec 31, 2006 | 14.44M | 14.18M | 5,488.76% |
| Dec 31, 2005 | 258.35K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.14B |
| Phibro Animal Health | 1.50B |
| Trulieve Cannabis | 1.14B |
| Prestige Consumer Healthcare | 1.10B |
| Alvotech | 562.04M |
| HUTCHMED (China) | 549.12M |
| Xeris Biopharma Holdings | 335.41M |
| Harrow | 275.59M |
ANIP News
- 5 days ago - ANI Pharmaceuticals price target lowered to $119 from $124 at Guggenheim - TheFly
- 5 days ago - ANI Pharmaceuticals price target lowered to $90 from $91 at Canaccord - TheFly
- 8 days ago - ANI Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - ANI Pharmaceuticals Earnings release: Q2 2026 - Filings
- 8 days ago - ANI Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 8 days ago - ANI Pharmaceuticals Slides: Q2 2026 - Filings
- 8 days ago - ANI Pharmaceuticals reports Q2 adjusted EPS $2.21, consensus $2.04 - TheFly
- 8 days ago - ANI Pharmaceuticals backs FY26 revenue view $1.08B-$1.14B, consensus $1.12B - TheFly